Company intelligence / Profile preview

Sea Pharmaceuticals

Cambridge, Massachusetts, United Statesseapharmaceuticals.com ↗

Ownership: Private
Development stage: Other

Overview

Sea Pharmaceuticals is developing proprietary synthetic small molecules targeting central nervous system disorders, specifically tinnitus, epilepsy, and sporadic ALS. The company’s lead programs are in the discovery and preclinical stages with a focus on novel oral neurotherapeutics. No published clinical results or late-stage trial data are available as of June 2025.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

SPM-0404

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Sea Pharmaceuticals collaborates with contract science labs for chemistry/neurobiology/pharmacology and works with business service firms for law, securities, insurance, accounting. No major pharma partnerships disclosed.

Beyond the preview

Go deeper on Sea Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sea Pharmaceuticals.

Explore the full profile